Dr. Asma Patel: What are the biggest barriers to rare disease drug development?
European Pharma Manufacturing and Drug Discovery World ask Quotient Sciences' Dr. Asma Patel, VP of Integrated Services for Early Development, about what barriers remain in rare disease drug development.
DCAT Value Chain Insights - CDMO Roundtable: Managing Orphan Drug Projects
Roundtable Interview with Paul Quigley, Principal Research Fellow, Drug Substance,& John McDermott, Executive Drug Development Consultant. Low-volume drugs, such as orphan drugs, present challenges in achieving favorable production economics and in managing the projects themselves. A roundtable of CDMOs provides perspectives on those challenges and best practices to resolve them.